Disease Domain | Count |
---|---|
Neoplasms | 3 |
Immune System Diseases | 2 |
Infectious Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Prophylactic vaccine | 1 |
Fusion protein | 1 |
DNA vaccine | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism KRAS inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ICAM-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism STAT3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date13 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date23 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
W4P-RBD | Coronavirus Infections More | Preclinical |
MD-3 (DiNonA) ( ICAM-1 ) | Liver transplant rejection More | Preclinical |
mKBscFv-CPP ( KRAS ) | Neoplasms More | Preclinical |
CMP-3013 | Acute Kidney Injury More | Preclinical |
JN-2 ( CXCR3 ) | Rheumatoid Arthritis More | Preclinical |